Roche, Sanofi, Pfizer, Novo Nordisk, and AstraZeneca all made headlines this week with key updates on earnings, regulatory approvals, and clinical data. The pharmaceutical industry remains dynamic, with companies strategically positioning themselves for future growth.
Regulatory Milestones
Pfizer's Abrysvo, a respiratory syncytial virus (RSV) vaccine, received FDA approval for expanded use in adults aged 18-59 who are at increased risk of RSV-associated lower respiratory tract disease (LRTD). This approval, based on Phase III MONeT study data, makes Abrysvo the only RSV vaccine available for this younger adult population, particularly those with underlying conditions like asthma, diabetes, or COPD. The CDC's ACIP also recommended expanding the use of pneumococcal vaccines from Pfizer and Merck for adults aged 50 and older.
AstraZeneca's Wainzua (eplontersen) received a positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP), recommending its approval for the treatment of hereditary transthyretin-mediated amyloidosis (ATTRv-PN). This debilitating disease causes peripheral nerve damage. The CHMP's recommendation was based on the NEURO-TTRansform study. The drug was already approved in the US under the name Wainua.
Clinical Trial Outcomes
Novo Nordisk announced positive results from the SOUL cardiovascular outcomes study, which evaluated oral semaglutide (Rybelsus) in adults with type 2 diabetes. The study met its primary endpoint, demonstrating a statistically significant 14% reduction in major adverse cardiovascular events (MACE) compared to placebo. The company plans to file regulatory applications in the US and EU to expand Rybelsus's label for cardiovascular risk reduction.
Corporate Strategy
Sanofi confirmed it is in exclusive negotiations with U.S. private equity firm CD&R to sell a controlling stake in its consumer healthcare (CHC) business, Opella. The deal values Opella at an enterprise value of approximately 16 billion euros. Sanofi will remain a significant shareholder in Opella, and the transaction is expected to close in the second quarter of 2025.
Financial Performance
Roche reported strong third-quarter and nine-month results, driven by high demand for its pharmaceuticals and diagnostics. Sales rose 9% at a constant exchange rate (CER) in the third quarter. Pharmaceutical division sales grew 7% in the first nine months, reaching CHF 34.3 billion, with Vabysmo (eye diseases), Phesgo (breast cancer), Ocrevus (multiple sclerosis), Hemlibra (hemophilia), and Polivy (blood cancer) contributing significantly. Roche maintained its sales growth guidance for 2024 in the mid-single-digit range (at CER).
